Medivir has posted a stellar snapshot of interim data from its Phase IIa study of a combo hep C treatment that adds Gilead's hot property--GS-7977--with the Swedish biotech's simeprevir (TMC435), which is partnered with Johnson & Johnson.
Vertex investors barely noted yesterday evening that revenue from Incivek slipped in the second quarter. Their attention was on ALS-2200, a hepatitis C nucleotide analogue that has elbowed its way into the frenzied race for a near-term approval for an all-oral therapeutic regimen.
It looks as if Gilead can't be shamed into a late-stage hepatitis C collaboration with Bristol-Myers Squibb after all.
Bristol-Myers Squibb isn't giving up on pushing Gilead Sciences to move ahead with further study of the two companies' oral drugs as a combo treatment for the hepatitis C virus.
The treatment that may well have the inside track in the hectic race to create the first all-oral combo treatment for hepatitis C.
Next week Gilead Sciences will release some of the most eagerly awaited trial data of the year when its clinical development team presents at the EASL in Barcelona.
Jefferies analyst Thomas Wei posted some positive results from an all-oral combo of Gilead's 7977 and Bristol-Myers Squibb's daclatasvir (BMS-52).
The news that two more hepatitis C patients had relapsed after they stopping taking an experimental medication in a tiny study wouldn't normally be the cause for considerable angst in the biotech...